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Background: Axillary reverse mapping (ARM) is a new technique to preserve upper extremity lymphatic pathways
during axillary lymph node dissection (ALND), thereby preventing lymphedema patients with breast cancer.
However, the oncologic safety of sparing the nodes identified by ARM (ARM nodes), some of which are positive,
has not been verified. We evaluated the metastatic status of ARM nodes and the efficacy of fine needle aspiration
cytology (FNAC) in assessing ARM node metastasis.
Methods: Sixty patients with breast cancer who underwent ARM during ALND between January 2010 and July
2012 were included in this study. Twenty-five patients were clinically node-positive and underwent ALND without
sentinel lymph node biopsy (SLNB). Thirty-five patients were clinically node-negative but sentinel node-positive on
the SLND. The lymphatic pathway was visualized using fluorescence imaging with indocyanine green. ARM nodes
in ALND field, whose status was diagnosed using FNAC, were removed and processed for histology. We evaluated
the correlation between the cytological findings of FNAC and the histological analysis of excised ARM nodes.
Results: The mean number of ARM nodes identified per patient was 1.6 ±0.9 in both groups. In most patients without
(88%) and with (79%) SLNB, the ARM nodes were located between the axillary vein and the second intercostobrachial
nerve. FNAC was performed for 45 ARM nodes, 10 of which could not be diagnosed. Six of the patients without SLNB
(24%) and onewith SLNB (3%) had positive ARM nodes. Of these sevenpatients, four had >3 positive ARM nodes. There
was no discordance between the cytological and histological diagnosis of ARM nodes status.
Conclusions: Positive ARM nodes were observed in the patients not only with extensive nodal metastasis but also in
those with a few positive nodes. FNAC for ARM nodes was helpful in assessing ARM nodes metastasis, which can be
beneficial in sparing nodes essential for lymphatic drainage, thereby potentially reducing the incidence of
lymphedema. However, the success of sampling rates needs to be improved.
Keywords: Breast cancer, Axillary reverse mapping, Fine needle aspiration cytology, Fluorescence imageBackground
Sentinel lymph node biopsy (SLNB) is currently consid-
ered as a standard of care to determine the spread of
cancer in patients with early stage breast cancer who
have clinical node-negative axilla. Recently, the American
College of Surgeons Oncology Group’s (ACOSOG)
Z0011 randomized trial reported that axillary lymph* Correspondence: bfaqt406@cwo.zaq.ne.jp
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reproduction in any medium, provided the ornode dissection (ALND) in patients with clinically node-
negative axilla could be omitted despite the presence of a
few positive sentinel nodes [1]. However, recent meta-
analysis of local treatments for breast cancer without
ACOSOG Z0011 trial showed that achieving good local
control with appropriate adjuvant therapy could improve
the prognosis of the patients with breast cancer [2]. Al-
though the significance of performing ALND for patients
with clinically node-negative and sentinel node-
positive must be debated, ALND has been still the
standard treatment for patients with clinically node-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 A comparison of clinicopathological features






Age (years) 57.2±11.3 61.5±12.1 NS
BMI 23.2±4.2 23.5±5.4 NS
T 0.09
0 2 (8) 0 (0)
1 6 (24) 17 (48.5)
2 14 (56) 17 (48.5)
3 2 (8) 0 (0)
4 1 (4) 1 (3)
N <0.001
0 0 35 (100)
1 20 (80) 0 (0)
2 2 (8) 0 (0)
3 3 (12) 0 (0)
Clinical stage <0.001
I 0 16 (46)
IIA 8 (32) 18 (51)
IIB 11 (44) 0
IIIA 2 (8) 0
IIIB 1 (4) 1 (3)
IIIC 3 (12) 0
Histology 0.33
IDC 23 (92) 35 (100)
Others 2a (8) 0 (0)
ER 0.10
Negative 7 (28) 3 (9)
Positive 18 (72) 32 (91)
HER-2 0.24
Negative 15 (60) 26 (74)
Positive 10 (30) 9 (26)
Numbers in brackets are percentages.
aThe histology of two patients’ breast cancer was invasive micropapillary
carcinoma and apocrine carcinoma.
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of concern with regard to the benefit for the patient.
Upper extremity lymphedema is one of the most severe
complications in patients with breast cancer who under-
gone ALND, and this complication has been reported in
6% to 49% of patients [3-6]. Breast cancer survivors with
lymphedema may experience different degrees of physical
and emotional disability that can severely affect the quality
of life [7]. Recently, the axillary reverse mapping (ARM)
has been developed to preserve arm lymphatic drainage
during ALND or SLNB [8-11]. Boneiti et al. [12] reported
that lymphedema developed in two of 12 patients follow-
ing the lymph node and/or lymphatic duct removal in
lymph drainage pathway identified by ARM. By compari-
son, lymphedema did occur in patients whose ARM nodes
remained intact during ALND. Thus, sparing ARM nodes
may reduce the incidence of lymphedema after
ALND [8-14]. The ARM procedure is based on the hy-
pothesis that the lymphatic pathway in the upper extrem-
ities would not involve metastasis from the primary breast
cancer nest [15]. However, previous studies reported meta-
static involvement in the ARM nodes in up to 43% of
patients [8-14]. Thus, the oncologic safety of retaining
lymph nodes or lymphatic ducts identified by ARM is an
important issue for an advancement of ARM as a standard
of care. To our knowledge, there are currently no reports
on any method to assess the oncologic safety of preserving
ARM nodes during ALND. Fine needle aspiration cytology
(FNAC) for axillary nodes is a popular and variable
technique to diagnosis lymph nodes metastasis before
surgery [16]. We analyzed nodal status of ARM nodes
and evaluated the efficacy of intraoperative FNAC for
ARM nodes to appraise the oncologic safety of ARM
node sparing during ALND.
Methods
Patients
Between January 2010 and July 2012, 372 patients with
breast cancer underwent breast surgery at our hospital.
In total, 116 of 372 patients required ALND, and 80 of
these patients underwent ARM and were enrolled in the
present study. Twenty patients who received primary
systemic treatment (chemotherapy or endocrine therapy)
were excluded. In total, 60 patients were included in the
final evaluation. The study was approved by the institu-
tional review board in our hospital. Written informed
consent was obtained from all patients that participated
in the study. We included patients with clinically or
cytologically node-positive axilla determined by FNAC
and patients with clinically node-negative axilla who had
positive sentinel nodes revealed by SLNB. Any patients
with an iodine allergy were ineligible for inclusion be-
cause of the use of indocyanine green as a tracing agent(ICG; Diagnogreen; Daiichi Sankyo, Co., Ltd., Tokyo,
Japan).
The mean ages of the patients without SLNB (with
clinically node-positive axilla) and with SLNB (with cli-
nically node-negative axilla and positive sentinel nodes)
were 57 ± 11 years and 62 ± 12 years, respectively. The
mean body mass indexes of the patients in two groups
were 23.2 ± 4.2 (without SLNB) and 23.5 ± 5.4 (with
SLNB). Characteristics of patients in the two groups are
shown in Table 1. Patients with SLNB had clinical stage
I (46%) and IIA (51%) breast cancer, whereas the clinical
stages of the patients without SLNB were IIA (32%), IIB
(44%), IIIA (8%), IIIB (4%), and IIIC (12%). Clinical
AB
C
Ikeda et al. World Journal of Surgical Oncology 2012, 10:233 Page 3 of 7
http://www.wjso.com/content/10/1/233breast cancer stage was determined according to the
Union for International Cancer Control (UICC) TNM
classification and staging [17].
ALND, Axillary lymph node dissection; BMI, Body
mass index; ER, Estrogen receptor; HER-2, Human epi-
dermal growth factor receptor 2; IDC, Invasive ductal
carcinoma; NS, Not significant; SLNB, Sentinal node
biopsy.
The patients without SLNB had significantly more
advanced breast cancer than patients with SLNB
(P <0.001). Estrogen receptor status and human epider-
mal growth factor receptor type 2 status were almost
similar between the two groups.Figure 1 Fluorescence imaging using the Photo Dynamic Eye
System. (A, B, C) White arrows indicate the site injected with
indocyanine green, ARM lymph nodes, and ARM lymphatic ducts,
respectively.Sentinel node biopsy procedure
In the patients with clinically node-negative axilla, 1 to 2 mL
of indigocarmine (Daiichi Sankyo, Co., Ltd., Tokyo,
Japan) was administered via intra-dermal injection to
the areolar region with a 26-gauge needle after the
induction of general anesthesia and before the patient
was prepared for surgery. ALND was performed if
either frozen sections or touch imprint cytology of the
sentinel nodes revealed metastasis. The procedure for
ALND is described below.Axillary reverse mapping and intraoperative fine needle
aspiration cytology for ARM nodes
Patients with clinically node-positive axilla initially received
an intra-dermal injection of 0.5 to 1.0 mL (5 mg/mL) ICG
at the upper and inner ipsilateral arm using a 1-mL sy-
ringe with a 26-gauge needle under general anesthesia
before preparation for breast surgery. After massaging
for approximately 5 min, the fluorescence signal was
detected using an invisible near-infrared fluorescence im-
aging system (PDETM; Photo Dynamic Eye; Hamamatsu
Photonics Company, Hamamatsu, Japan) as flowing to
the axilla from the upper extremity. Patients who had
positive sentinel nodes as shown on SLNB received an
ICG injection before ALND in a manner similar to that
for patients with clinically node-positive axilla.
After performing lumpectomy or mastectomy for
breast cancer, we started to explore ARM nodes in the
axillary field. ARM nodes and lymphatic ducts were
identified as fluorescent objects in the axilla even if they
did not exhibit a green-colored stain (Figure 1). The
locations of all identified ARM nodes were marked on
the map according to the surgical landmarks of the axil-
la, which include the axillary vein, the thoracodorsal
neurovascular bundle, and the second intercostobrachial
nerve (Figure 2). The limits of ALND were defined by
the axillary vein, superiorly; the anterior serratus muscle,
medially; and the anterior edge of the latissimus dorsi
muscle, laterally. When fluorescent ARM nodes werelocated in the ALND field, they were separately removed
after performing FNAC to evaluate the pathological find-
ings. FNAC was performed using a 23-gauge needle
attached to a 10-mL aspirating syringe (Figure 3). On
the other hand, when identified ARM nodes were out-
side the ALND field, they were spared, and we did not
perform FNAC.
Pathology evaluation
We retrospectively evaluated the correlation between
the cytological findings on FNAC and the histological
results of removed ARM nodes. Cytological findings of
classic Papanicolau and Giemsa staining were inter-
preted by two pathologists with an established expe-
rience in breast cytology. The cytological results were
reported as negative, suspicious, positive for malignancy,
or inadequate for diagnosis. Histological findings were
diagnosed using hematoxylin and eosin staining at the
maximum longitudinal section of each node.
Statistical analysis
Stat Mate version IV for Windows was used for data
analyses. To estimate the differences in the clinicopatho-
logical and categorical data associated with the ARM
procedure between the groups with or without SLNB,
we used the chi-square or the Mann-Whitney U test.
Two-tailed P values <0.05 were considered statistically
significant.
Results
Of 60 patients, 25 underwent ALND because of clinic-
ally node-positive axilla (without SLNB group), whereas
35 required ALND because of positive sentinel nodes on
SLNB (with SLNB group). Fluorescence imaging using
the PDETM System identified ARM nodes and lymphatic
The axillary vein 
The 2nd intercostal
brachial nerve
The anterior edge of









Figure 2 Mapping of the ARM lymph nodes in the axilla. Field A is the area between the axillary vein and the second intercostobrachial
nerve and between the anterior edge of the latissimus dorsi muscle and the thoracodorsal neurovascular bundle. Field B is the area medially
adjacent to field A and close to the anterior serratus muscle (the chest wall). Field C is the area surrounding the second intercostobrachial nerve,
the anterior serratus muscle, and the thoracodorsal neurovascular bundle. Field D is the area below field A and laterally adjacent to field C. Field E
is the area above the axillary vein.
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patients without SLNB and among those with SLNB,
respectively. The total number of identified ARM nodes
were 35 in the without SLNB group and 42 in the with
SLNB group. The mean number of identified ARM
nodes per person was 1.6± 0.9 in both groups.
In most patients, the ARM nodes were located be-
tween the axillary vein and the second intercostobrachial
nerve (Figure 2). Five ALND fields were described as fol-
lows: field A, the area between the axillary vein and the
second intercostobrachial nerve, and close to the ante-
rior edge of the latissimus dorsi muscle; field B, the area
medially adjacent to field A and close to the anterior ser-
ratus muscle; field C, the area below the second inter-
costobrachial nerve and close to the anterior serratusFigure 3 The picture of performing intraoperative FNAC for
ARM node. This picture shows performing intraoperative FNAC for
an ARM node (indicated with a white arrow) with a 23-gauge
needle in the surgical field.muscle; field D, the area below the second intercostobra-
chial nerve and close to the anterior edge of the latissi-
mus dorsi muscle; field E, the area above the axillary
vein. Field distribution of ARM node for the two groups
is shown in Table 2. The distribution of ARM nodes
identified in patients without SLNB was as follows: field
A, 63%; field B, 25%; field C, 6%; field D, 0%; field E, 6%.
In comparison, the distribution of ARM nodes identified
in patients with SLNB was as follows: field A, 60%; field
B, 19%; field C, 2%; field D, 2%; field E, 17%. Four (16%)
patients without SLNB and 11 (31%) patients with SLNB
displayed nodes outside the ALND field that were not
assessed by FNAC.
Six (24%) patients without SLNB had positive ARM
nodes, whereas only one (3%) patient with SLNB showed
metastasis to the ARM node. The patients without SLNB
had a significantly higher frequency of positive ARM
nodes than those with SLNB (P = 0.035) (Table 2). The
features of the seven patients with positive ARM nodes
are summarized in Table 3. In all these cases, the ARM
nodes were located in field A (Figure 2) and the metastatic
characteristic of the ARM nodes was defined as macrome-
tastasis (with foci >2 mm). Case 2 listed in Table 2 had a
single positive ARM node located in field A (Figure 2),
whereas no metastasis were noted in the other axillary
nodes that were removed. In the patients without and with
SLNB, FNAC was performed for 23 and 22 ARM nodes,
respectively, of which 17 (74%) and 18 (82%) nodes could
be diagnosed using were FNAC, respectively. The remain-
der of nodes could not be assessed because of inadequate
material (Table 2). For the 35 ARM nodes that could be
assessed by FNAC, no discordance was noted between the
cytological assessments by FNAC and the histological








ARM node 22 (88) 26 (74) 0.33
ARM lymphatic duct 19 (76) 30 (86) 0.54
Preservation
ARM node 4 (16) 11 (31) 0.29






A 22 (63) 25 (60)
B 9 (25) 8 (19)
C 2 (6) 1 (2)
D 0 (0) 1 (2)
E 2 (6) 7 (17)
Metastasis 0.035
6 (24) 1 (3)
FNAC
Tested node number 23 (66) 22 (52) 0.23
Negative 13 (57) 17 (77) 0.26
Positive 4 (17) 1 (5)
Inadequate 6 (26) 4 (18)
Numbers in brackets are percentages.
FNAC, Fine needle aspiration cytology; NS, Not significant; SLNB, Sentinel node
biopsy.
Table 3 Review of the cases with positive ARM nodes
Case Age (years) Clinical stage
(TNM)
Surgery SLNB Number / locationa
of ARM nodes
1 40 IIB (T2N1M0) Bp - 1/ A
2 65 IIB (T2N1M0) Bt - 1/ A
3 55 IIB (T2N0M0) Bt + 2/ A, E
4 70 IIIB (T4N1M0) Bt - 2/ A,B
5 66 IIB (T2N1M0) Bp - 1/ A
6 79 IIIC (T2N3M0) Bt - 1/ A
7 52 IIA (T0N1M0) Ax - 1/ A
aLocation of ARM nodes; Field A, B, C, D, and E are presented in Figure 2.
bA single ARM node had metastasis of breast cancer although the other removed a
cThe metastatic ARM node (located in field A) was positive by FNAC, whereas anoth
involve metastatic foci pathologically.
dThe removed ARM node included two lymph nodes microscopically and there wer
Bp, Lumpectomy; Bt, mastectomy; FNAC, Fine needle aspiration cytology; Mac, Mac
Ikeda et al. World Journal of Surgical Oncology 2012, 10:233 Page 5 of 7
http://www.wjso.com/content/10/1/233results. There was no evidence of metastasis in the 30
ARM nodes diagnosed as a negative for malignancy by
FNAC; on the other hand, five ARM nodes diagnosed as
either suspicious or positive by FNAC involved breast can-
cer metastasis.Discussion
According to previous ARM studies using dyes and
radioisotopes, the incidence of ARM nodes detect in
patient populations were reported to be 50% to 91%
[8-14]. The detection of ARM lymphatic ducts is more
important than that of ARM nodes because the aim of
ARM is to spare lymphatic pathways, which is not the
case for the SLNB procedure. Noguchi et al. reported
that the identification rate of ARM nodes and/or lym-
phatics was 88% using fluorescence navigation with ICG,
and concluded that the fluorescence imaging technique
was useful for detecting not only the ARM lymph nodes,
but also the lymphatic ducts [13]. In the present study,
the identification rates of ARM nodes and lymphatic
ducts were 88% and 76% for patients without SLNB
and 74% and 86% for patients with SLNB, respectively,
which was similar to the results in previous studies.
The fundamental concept of ARM procedure is based
on the assumption that the lymphatic pathway from
the upper extremity would not involve metastasis from
the primary breast cancer [8,11,12]. However, the meta-
static rates to ARM nodes were reported to be around
14% to 43% in recent feasibility studies [10,13,14]. The
oncologic safety of preserving ARM nodes or lymphatic
ducts is the most important issue for performing ARM
in practice. Nos et al. [10] explained the assumptions
concerning ARM node metastasis. The first assumption
was that ARM nodes would belong to the central nodal









Positive 1/1 2/14 Mac
Inadequate 1/1 1/13b Mac




Suspected 1/1 15/19 Mac
Suspected 2/2d 20/27 Mac
Inadequate 1/1 2/17 Mac
xillary lymph nodes had no metastasis.
er ARM node (located in field B) diagnosed as negative by FNAC did not
e metastasis in both ARM nodes.
rometastasis; SLNB sentinel lymph node biopsy.
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ARM procedure would have limited surgical benefit.
A further assumption was that the natural progression
of breast cancer would lead a metastasis to ARM node
following the other extensive nodal metastasis. In the
present study, the patients with clinically node-positive
axilla had a higher risk (24%) of having positive ARM
nodes than those with clinically node-negative axilla
(3%). Of 35 patients with SLNB, only one patient had a
positive ARM node (Table 3). She had a silicone im-
plant in the bilateral breast and it was difficult to esti-
mate the nodal status using ultrasonography (US) and
computed tomography before surgery. She had severe
nodal metastasis (nine positive nodes) at levels I to III
of the axilla.
In the seven patients with positive ARM nodes, four
(57%) had extensive nodal metastasis (> 4 metastatic
nodes). This result may support the notion that patients
with breast cancer and extensive nodal metastasis would
have positive ARM nodes following tumor progression.
However, the other three patients also had a few positive
nodes in the axilla. In these patients, there must be
another reason why ARM node status was positive. In
previous ARM studies, ARM nodes and/or ducts were
observed in the sentinel biopsy field in 38% to 75% of all
cases [11-13] and concordance between sentinel nodes
and ARM nodes was reported in approximately 20% of
the patients [13]. The positive ARM node in noted in
case 2 (Table 3) was not located in the sentinel lymph
node biopsy field, which seems to equate to field B or C
(Figure 2), but rather to field A, where ARM nodes were
often observed (Figure 2). This case may suggest that
some ARM nodes belong to the breast central nodes
and that metastasis to ARM nodes could occur in the
patients with a few positive axillary nodes. Therefore, it
is important to confirm the metastatic status of ARM
nodes in order to for those nodes to be retained during
operation. Han et al. reported the use of FNAC or fro-
zen biopsy of partial resection of suspicious ARM nodes
to confirm oncologic safety if the surgeon suspected that
those nodes were metastatic. Unfortunately, the detail
information from that study concerning the FNAC
results for ARM nodes is not available [18].
In practice, FNAC of axillary lymph nodes with US
guidance is widely accepted as a useful procedure for
providing preoperative information on nodal status [16].
A recent systematic review of the US-guided FNAC
shows a sensitivity that varies between 30.6% and 62.9%
and a specificity of 100% [19]. However, inadequate
sampling is a potential limitation of FNAC for diagno-
sis. Ciatto et al. [16] reported that a sampling error
might be corrected by repeated sampling and showed
that sampling was insufficient in 10.8% of cases, which is
comparable or lower than the inadequacy rate reportedin other studies. In our study, the sampling error was
26% in the without SLNB group and 18% in with SLNB
group. Micrometastasis in a lymph node was one of the
causes for false-negative result in a previous study of
FNAC for axillary lymph nodes [20]. However, the chief
cause of our sampling error may be technical in nature
because all patients had macrometastasis in the ARM
nodes in the present study. Our sampling error rate
was higher than that of FNAC by US-guided aspiration.
Compared with an US-guided procedure, it may be dif-
ficult to obtain sufficient materials from lymph nodes in
a surgical field using our method, because US imaging
can be helpful in confirming the fine needle tract to the
target. Repeat aspiration for ARM nodes may improve
the success rate of sampling if sufficient material for
diagnosis is not harvested after the first aspiration. The
limitation of our study included the small number of
enrolled patients and relative inexperience with the new
procedure. Studies including a larger series of patients
are required to determine the efficacy of FNAC for the
preservation of ARM nodes during ALND.
Conclusion
Metastasis to ARM nodes can occur both in patients
with extensive nodal metastasis and in those with a few
positive nodes. However, patients with clinically node-
positive breast cancer had a significantly greater inci-
dence of positive ARM nodes than those with clinically
node-negative and sentinel node-positive breast cancer.
FNAC for ARM nodes might be helpful for the assess-
ment of metastasis in ARM nodes, but an improvement
in the sample success rate is needed for a robust
confirmation.
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